Dr. James Cai Joins aTyr Pharma to Drive Clinical Developme... ( Former AstraZeneca Exec to Lead Hong ...)

Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia

Date:3/10/2009

Former AstraZeneca Exec to Lead Hong Kong-based subsidiary Pangu BioPharma

SAN DIEGO, March 10 /PRNewswire/ -- aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of an entirely new class of natural protein therapeutics (biologics) for multiple disease indications, today announced that Dr. James Cai has joined the Company as Senior Vice President of Clinical Development at aTyr Pharma and President of Pangu BioPharma, a fully owned aTyr Pharma subsidiary in Hong Kong.

With over a decade of experience developing and leading research and development in Asia for leading pharmaceutical companies, Dr. Cai's industry and regional expertise will position both aTyr Pharma and Pangu BioPharma to fully take advantage of the unique growth opportunities of Asia. Most recently, Dr. Cai was Vice President of Research and Development at AstraZeneca China. In this role he established the Research and Development organization in China and was responsible for Clinical Research, Medical-Marketing, Regulatory Affairs, Patient Safety and Business Development. During his tenure, the team launched Iressa and Crestor, with $265 M and $3.6 B in global annual sales respectively

"We are thrilled to have Dr. James Cai join aTyr Pharma and Pangu BioPharma as a key member of our management team," said Dr. Jeff Watkins, CEO of aTyr Pharma. "His many years of hands on clinical development, paired with deep relationships in Asia and a proven ability to drive drug discovery forward in the region make Dr. Cai perfectly suited for his role as the leader of our subsidiary Pangu BioPharma."

Prior to joining AstraZeneca, Dr. Cai was External Affairs and HIV Franchise Director at Merck Sharp & Dohme China and Medical Director at Pfizer. Dr. Cai graduated from Columbia University with Executive MBA, and trained as physician and clinical researcher from Shanghai Second Me
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
2. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
5. ARCA biopharma Appoints James Carr as Vice President of Marketing
6. James C. Powell Joins Nerites Board of Directors
7. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
8. Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
9. James T. Glover Appointed to Board of Directors of Varian, Inc.
10. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group

Post Your Comments:

Dr. James Cai Joins aTyr Pharma to Drive Clinical Developme...( Former AstraZeneca Exec to Lead Hong ...)